Bon Secours Liver Institute of Virginia - Richmond — Richmond, Virginia

Bon Secours Liver Institute of Virginia - Richmond is a clinical research site located in Richmond, Virginia, United States 23226.

Crixeo Clinical Trials Trust Score: 6/100 (FAILING). This profile has not yet been claimed by the site owner.

Bon Secours Liver Institute of Virginia - Richmond has participated in 2 clinical trials.

Therapeutic areas: Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis.

Sponsors: Galectin Therapeutics Inc., Genfit.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Richmond

Browse all research sites in Virginia · View every site in Richmond

Sponsor Feasibility Report

Trust Score: 6/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Bon Secours Liver Institute of Virginia - Richmond?

Bon Secours Liver Institute of Virginia - Richmond has a Crixeo Trust Score of 6/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Bon Secours Liver Institute of Virginia - Richmond conducted?

Bon Secours Liver Institute of Virginia - Richmond has 2 clinical trials on record. Their work covers Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis.

Is Bon Secours Liver Institute of Virginia - Richmond accredited by Crixeo Clinical Trials?

Bon Secours Liver Institute of Virginia - Richmond has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Bon Secours Liver Institute of Virginia - Richmond?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.